Characterization of functional methylomes by next-generation capture sequencing identifies novel disease-associated variants
Allum F., Shao X., Guénard F., Simon M-M., Busche S., Caron M., Lambourne J., Lessard J., Tandre K., Hedman ÅK., Kwan T., Ge B., Ahmadi KR., Ainali C., Barrett A., Bataille V., Bell JT., Buil A., Dermitzakis ET., Dimas AS., Durbin R., Glass D., Hassanali N., Ingle C., Knowles D., Krestyaninova M., Lindgren CM., Lowe CE., Meduri E., di Meglio P., Min JL., Montgomery SB., Nestle FO., Nica AC., Nisbet J., O'Rahilly S., Parts L., Potter S., Sandling J., Sekowska M., Shin S-Y., Small KS., Soranzo N., Surdulescu G., Travers ME., Tsaprouni L., Tsoka S., Wilk A., Yang T-P., Zondervan KT., Rönnblom L., McCarthy MI., Deloukas P., Richmond T., Burgess D., Spector TD., Tchernof A., Marceau S., Lathrop M., Vohl M-C., Pastinen T., Grundberg E.
AbstractMost genome-wide methylation studies (EWAS) of multifactorial disease traits use targeted arrays or enrichment methodologies preferentially covering CpG-dense regions, to characterize sufficiently large samples. To overcome this limitation, we present here a new customizable, cost-effective approach, methylC-capture sequencing (MCC-Seq), for sequencing functional methylomes, while simultaneously providing genetic variation information. To illustrate MCC-Seq, we use whole-genome bisulfite sequencing on adipose tissue (AT) samples and public databases to design AT-specific panels. We establish its efficiency for high-density interrogation of methylome variability by systematic comparisons with other approaches and demonstrate its applicability by identifying novel methylation variation within enhancers strongly correlated to plasma triglyceride and HDL-cholesterol, including at CD36. Our more comprehensive AT panel assesses tissue methylation and genotypes in parallel at ∼4 and ∼3 M sites, respectively. Our study demonstrates that MCC-Seq provides comparable accuracy to alternative approaches but enables more efficient cataloguing of functional and disease-relevant epigenetic and genetic variants for large-scale EWAS.